

[illegible][illegible]

**EXAMINER
SIGNATURE**

~~DATE~~ CONSIDERED

SIGNATURE [Signature]

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ² See Kinds and Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English Language Translation is attached.

Applicants: Michael J. Elliott, et al.
Serial No.: 08/602,272
Filed: February 16, 1996
Exhibit A

Form PTO-1449

U.S. Department of Commerce
Patent and Trademark OfficeINFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)

Application Number	08/602,272
Filing Date	February 16, 1996
First Named Inventor	Michael J. Elliott
Art Unit	1642
Examiner Name	K. Canella
Attorney Docket No.	1481/65021/JPW/AJ M/CY

NON PATENT LITERATURE DOCUMENTS


Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
KAC	2	BERTINI, R., ET AL., "Depression Of Liver Drug Metabolism And Increase In Plasma Fibrinogen By Interleukin 1 And Tumor Necrosis Factor: A Comparison With Lymphotoxin And Interferon," <u>Int J. Immunopharmac.</u> (1988), 19(5):525-530 (EXHIBIT 2);	
	3	BERTINI, R., ET AL., "Dexamethasone modulation of in vivo effects of endotoxin, tumor necrosis factor, and interleukin-1 on liver cytochrome P-450, plasma fibrinogen, and serum iron," <u>J. Leukoc. Biol.</u> (1989), 46(3):254-62 (EXHIBIT 3);	
	4	GRESSER, I., ET AL., "Tumor necrosis factor induces acute phase proteins in rats," <u>J. Biol. Regul. Homeost. Agents</u> (1987), 1(4):173-6 (EXHIBIT 4);	
	5	NAWROTH, P., ET AL., "Tumor Necrosis Factor/Cachectin-Induced Intravascular Fibrin Formation In Meth A Fibrosarcomas," <u>J. Exp. Med.</u> (1988), 168:637-647 (EXHIBIT 5);	
	6	SEKUT, L., ET AL., "Anti-inflammatory activity of phosphodiesterase (PDE)-IV inhibitors in acute and chronic models of inflammation," <u>Clin. Exp. Immunol.</u> (1995), 100(1):126-32 (EXHIBIT 6);	
	7	SORIA, J., ET AL., "Pentoxifylline, fibrinogen and leukocytes," <u>Blood Coagul. Fibrinolysis</u> (1990), 1(4-5):485-7 (EXHIBIT 7);	
	8	VAN DER POLL, T., ET AL., "Fibrinolytic Response to Tumor Necrosis Factor in Healthy Subjects," <u>J. Exp. Med.</u> (1991), 174:729-732 (EXHIBIT 8);	
	9	VAN HINSBERGH, V.W., ET AL., "Progress of fibrinolysis during tumor necrosis factor infusions in humans. Concomitant increase in tissue-type plasminogen activator, plasminogen activator inhibitor type-1, and fibrin(ogen) degradation products," <u>Blood</u> (1990), 76(11):2284-9 (EXHIBIT 9); and	
✓	10	ZABEL, P. et al., "Inhibition of endogenous TNF formation by pentoxifylline," <u>Immunobiology</u> (1993), 187(3-5):447-63, review (EXHIBIT 10).	

EXAMINER
SIGNATURE*K. Canella*

DATE CONSIDERED

9/2/2005

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²Applicant is to place a checkmark here if English language Translation is attached.



Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office		Atty. Docket No. 65021/JPW/AJM/DNS		Serial No. 08/602,272	
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)				Applicants: Michael J. Elliot et al.			
				Filing Date February 26, 1996		Group 1642	
U.S. PATENT DOCUMENTS							
Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
FOREIGN PATENT DOCUMENTS							
		Document Number	Date	Country	Class	Subclass	Translation
							Yes No
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
KAC		Centocor, Inc.'s Remicade (infliximab) Products Webpage, http://www.centocor.com/cgi-in/site/products/prod_remicade.cgi (June 22, 2004)					
		October 28, 1999 Pharmacological Review for Remicade (infliximab) from the U.S. Food and Drug Administration's Center For Drug Evaluation And Research, http://www.fda.gov/cder/biologics/review/inflcen111099r2.pdf (June 21, 2004)					
		Label and Approval History for Remicade (infliximab) from the U.S. Food and Drug Administration's Center for Evaluation And Research, http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Label_ApprovalHistory#apphist (June 21, 2004)					
EXAMINER		DATE CONSIDERED					
<i>[Signature]</i>		<i>9/2/2005</i>					
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

Applicants: Michael J. Elliott, et al.
Serial No.: 08/602,272
Filed: February 16, 1996
Exhibit B